PTC Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1998-01-01

Employees: 1K

Market Cap: $2.7B

Website: http://www.ptcbio.com

Introduction: PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Clinical Trials

Extension Study of Ataluren (PTC124) in Cystic Fibrosis

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Ataluren

First Posted Date: 2010-06-09

Last Posted Date: 2020-10-19

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 191

Registration Number: NCT01140451

Locations: 🇺🇸
Emory University Cystic Fibrosis Center, Atlanta, Georgia, United States
🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States

and more 28 locations

Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD)

Phase 2

Terminated

Conditions: Duchenne Muscular Dystrophy
Becker Muscular Dystrophy

Interventions: Drug: Ataluren
Drug: Chronic Corticosteroid Therapy

First Posted Date: 2009-11-06

Last Posted Date: 2020-07-29

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 6

Registration Number: NCT01009294

Locations: 🇬🇧
University of Newcastle, Newcastle upon Tyne, United Kingdom
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States

and more 3 locations

Study of Ataluren (PTC124) in Hemophilia A and B

Phase 2

Terminated

Conditions: Hemophilia A
Hemophilia B

Interventions: Drug: Ataluren

First Posted Date: 2009-07-27

Last Posted Date: 2020-06-16

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 13

Registration Number: NCT00947193

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
The Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States
🇮🇹
Azienda Ospedaliero-Universitaria Careggi Viale G.B. Morgagni, Firenze, Italy

and more 10 locations

PTC299 for Treatment of Neurofibromatosis Type 2

Phase 2

Terminated

Conditions: Neurofibromatosis 2

Interventions: Drug: PTC299

First Posted Date: 2009-06-01

Last Posted Date: 2019-04-12

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 11

Registration Number: NCT00911248

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)

Phase 2

Terminated

Conditions: Duchenne Muscular Dystrophy
Becker Muscular Dystrophy

Interventions: Drug: Ataluren

First Posted Date: 2009-02-19

Last Posted Date: 2020-07-15

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 173

Registration Number: NCT00847379

Locations: 🇪🇸
Hospital Universitario La Fe, Valencia, Spain
🇦🇺
The Children's Hospital at Westmead, Westmead, Australia
🇺🇸
Child Neurology Center of NW Florida, Gulf Breeze, Florida, United States

and more 34 locations

Study of Ataluren (PTC124™) in Cystic Fibrosis

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Ataluren
Drug: Placebo

First Posted Date: 2008-12-05

Last Posted Date: 2020-05-14

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 238

Registration Number: NCT00803205

Locations: 🇺🇸
Miller Children's Hospital Long Beach, Long Beach, California, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
University of Texas, Tyler, Texas, United States

and more 35 locations

Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (DMD)

Phase 2

Terminated

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Ataluren

First Posted Date: 2008-09-25

Last Posted Date: 2020-10-29

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 36

Registration Number: NCT00759876

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

PTC299 for Treatment of Advanced Cancer

Phase 1

Terminated

Conditions: Advanced Cancer

Interventions: Drug: PTC299
Drug: Docetaxel

First Posted Date: 2008-06-25

Last Posted Date: 2019-05-10

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 76

Registration Number: NCT00704821

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)

Phase 2

Completed

Conditions: Duchenne Muscular Dystrophy
Becker Muscular Dystrophy

Interventions: Drug: Placebo
Drug: Ataluren

First Posted Date: 2008-01-14

Last Posted Date: 2020-04-07

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 174

Registration Number: NCT00592553

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇦🇺
Royal Children's Hospital, Parkville, Victoria, Australia
🇺🇸
Children's Hospital of Boston/Harvard Medical School, Boston, Massachusetts, United States

and more 34 locations

PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: PTC299

First Posted Date: 2007-07-30

Last Posted Date: 2016-03-03

Lead Sponsor: PTC Therapeutics

Target Recruit Count: 33

Registration Number: NCT00508586

Locations: 🇺🇸
New York University Clinical Cancer Center, New York, New York, United States
🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy